Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01734447
First received: November 22, 2012
Last updated: November 26, 2012
Last verified: November 2012
  Purpose

This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.


Condition Intervention Phase
Foetal Growth Problem
Small for Gestational Age
Drug: somatropin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Glucose tolerance as assessed by hyperglycaemia induced by oral ingestion [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Bone Age determined according to Greulich and Pyle method and measured on the left hand X-ray [ Designated as safety issue: No ]
  • Pubertal development, assessed according to Tanner method [ Designated as safety issue: No ]
  • Height velocity [ Designated as safety issue: No ]
  • Final height [ Designated as safety issue: No ]
  • Number of Adverse Events [ Designated as safety issue: No ]

Enrollment: 57
Study Start Date: April 2000
Study Completion Date: April 2003
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1.2, continuous treatment Drug: somatropin
1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
Experimental: 1.2, non-continuous treatment Drug: somatropin
1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
Experimental: 2.4, non-continuous treatment Drug: somatropin
2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients born with IUGR enrolled in trial GHRETARD/F/1/F
  • Bone age below 14 years in boys and 12 years in girls

Exclusion Criteria:

  • Bone age above 14 years in boys and 12 years in girls
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01734447

Locations
France
Paris, France
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Catherine Boisson-Lesage, MD Novo Nordisk Pharmaceutique SAS
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01734447     History of Changes
Other Study ID Numbers: GHRETARD/F/2/F
Study First Received: November 22, 2012
Last Updated: November 26, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Fetal Growth Retardation
Fetal Diseases
Pregnancy Complications
Growth Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on July 29, 2014